Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
← catalyst calendarSponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
404actual
Sites
106
Countries
Australia, China, France +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-12-19 | actual | When the study began enrolling |
| Primary completion | 2026-05-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-23 | actual | The whole study's end, after follow-up |
| First posted | 2019-11-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Malignancies
Interventions
- Drug: Tislelizumab — also filed as BGB-A317
- Drug: Pamiparib — also filed as BGB-290
- Drug: Temozolomide
- Drug: Sitravatinib
- Drug: Ociperlimab — also filed as BGB-A1217
- Drug: BAT1706
- Drug: Fruquintinib
- Drug: BGB-15025
- Drug: Zanidatamab — also filed as ZW25
- Drug: BGB-A445 — also filed as Gimistotug
- Drug: Surzebiclimab — also filed as BGB-A425
- Drug: Lenvatinib
- Drug: LBL-007 — also filed as Alcestobart
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Immune-Mediated Adverse Events, Serious Adverse Events, and Adverse Events Grade 3 or Higher
measured up to 7 years
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed